JOGC

Vulvovaginitis: Screening for and Management of Trichomoniasis, Vulvovaginal Candidiasis, and Bacterial Vaginosis

      Abstract

      Objective

      To review the evidence and provide recommendations on screening for and management of vulvovaginal candidiasis, trichomoniasis, and bacterial vaginosis.

      Outcomes

      Outcomes evaluated include the efficacy of antibiotic treatment, cure rates for simple and complicated infections, and the implications of these conditions in pregnancy.

      Evidence

      Published literature was retrieved through searches of MEDLINE, EMBASE, CINAHL, and The Cochrane Library in June 2013 using appropriate controlled vocabulary (e.g., vaginitis, trichomoniasis, vaginal candidiasis) and key words (bacterial vaginosis, yeast, candidiasis, trichomonas vaginalis, trichomoniasis, vaginitis, treatment). Results were restricted to systematic reviews, randomized control trials/controlled clinical trials, and observational studies. There were no date limits, but results were limited to English or French language materials. Searches were updated on a regular basis and incorporated in the guideline to May 2014. Grey (unpublished) literature was identified through searching the websites of health technology assessment and health technology-related agencies, clinical practice guideline collections, and national and international medical specialty societies.

      Values

      The quality of evidence in this document was rated using the criteria described in the Report of the Canadian Task Force on Preventive Health Care (Table 1).

      Key words

      To read this article in full you will need to make a payment

      REFERENCES

        • Sobel J.D.
        Management of patients with recurrent vulvovaginal candidiasis.
        Drugs. 2003; 63: 1059-1066
        • Ohmit S.
        • Sobel J.
        • Schuman P.
        • Duerr A.
        • Mayer K.
        • Rompalo A.
        • et al.
        HIV Epidemiology Research Study (HERS) Group. Longitudinal study of mucosal Candida species colonization and candidiasis among human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women.
        J Infect Dis. 2003; 188: 118-127
        • De Leon E.
        • Jacober S.J.
        • Sobel J.D.
        • Foxman B.
        Prevalence and risk factors for vaginal Candida colonization in women with type 1 and type 2 diabetes.
        BMC Infect Dis. 2002; 2: 1
        • Odds F.C.
        Candidosis of the fenitalia.
        in: Odds F.C. Candida candidosis: a review and bibliography. 2nd ed. Bailliere Tindal, London1988: 124
        • Vermitsky J.P.
        • Self M.J.
        • Chadwick S.G.
        • Trama J.P.
        • Adelson M.E.
        • Mordechai E.
        • et al.
        Survey of vaginal-flora Candida species isolates from women of different age groups by use of species-specific PCR detection.
        J Clin Microbiol. 2008; 46: 1501-1503
        • Sobel J.D.
        Vulvovaginal candidosis.
        Lancet. 2007; 369: 1961-1971
        • Public Health Agency of Canada
        Canadian guidelines on sexually transmitted infections—updated January 2010. PHAC, Ottawa2010 (Accessed on November 6, 2013) (Available at:)
        • Nyirjesy P.
        • Sobel J.D.
        Genital mycotic infections in patients with diabetes.
        Postgrad Med. 2013; 125: 33-46
        • Watts D.H.
        • Springer G.
        • Minkoff H.
        • Hillier S.L.
        • Jacobsen L.
        • Moxley M.
        • et al.
        The occurrence of vaginal infections among HIV-infected and high-risk uninfected women: longitudinal findings of the Women’s Interagency HIV Study.
        J Aquir Immune Defic Syndr. 2006; 43: 161-168
        • Sobel J.D.
        • Kapernick P.S.
        • Zervos M.
        • Reed B.D.
        • Hooton T.
        • Soper D.
        • et al.
        Treatment of complicated Candida vaginitis: comparison of single and sequential doses of fluconazole.
        Am J Obstet Gynecol. 2001; 185: 363-369
        • Pirotta M.V.
        • Garland S.M.
        Genital Candida species detected in samples from women in Melbourne, Australia, before and after treatment with antibiotics.
        J Clin Microbiol. 2006; 44: 3213-3217
        • Nurbai M.
        • Grimshaw J.M.
        • Watson M.
        • Bond C.M.
        • Mollison J.
        • Ludbrook A.
        Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush).
        Cochrane Database Syst Rev. 2007; 4: CD002845
        • Sobel J.D.
        • Wiesenfeld H.C.
        • Martens M.
        • Danna P.
        • Hooton T.M.
        • Rompalo A.
        • et al.
        Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis.
        N Engl J Med. 2004; 351: 876-883
        • Pappas P.G.
        • Rex J.H.
        • Sobel J.D.
        • Filler S.G.
        • Dismukes W.E.
        • Walsh T.J.
        • et al.
        Infectious Diseases Society of America. Guidelines for treatment of candidiasis.
        Clin Infect Dis. 2004; 38: 161-189
        • Guaschino S.
        • De Seta F.
        • Sartore A.
        • Ricci G.
        • De Santo D.
        • Piccoli M.
        • et al.
        Efficacy of maintenance therapy with topical boric acid in comparison with oral itraconazole in the treatment of recurrent vulvovaginal candidiasis.
        Am J Obstet Gynecol. 2001; 184: 598-602
        • Sobel J.D.
        Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy.
        N Engl J Med. 1986; 315: 1455-1458
        • Roth A.C.
        • Milsom I.
        • Forssman L.
        • Wahlen P.
        Intermittent prophylactic treatment of recurrent vaginal candidiasis by postmenopausal application of a 500 mg clotrimazole vaginal tablet.
        Genitourin Med. 1990; 66: 357-360
        • Molgaard-Nielsen D.
        • Pasternak B.
        • Hviid A.
        Use of oral fluconazole during pregnancy and the risk of birth defects.
        N Eng J Med. 2013; 369: 830-839
        • Acs N.
        • Banhidy F.
        • Puho E.
        • Czeizel A.E.
        Teratogenic effects of vaginal boric acid treatment during pregnancy.
        Int J Gynaecol Obstet. 2006; 93: 55-56
        • Sutton M.
        • Sternberg M.
        • Koumans E.H.
        • McQuillan G.
        • Berman S.
        • Markowitz L.E.
        The prevalence of Trichomonas vaginalis infection among reproductive age women in the United States, 2001-2004.
        Clin Infect Dis. 2007; 45: 1319-1326
        • Gerbase A.C.
        • Rowley J.T.
        • Heymann D.H.
        • Berkeley S.B.F.
        • Piot P.
        Global prevalence and incidence estimates of selected curable STDs.
        Sex Transm Dis. 1998; 74: S12-S16
        • Peterson P.
        Trichomonas vaginalis vaginitis. A comparative study of treatment and incidence.
        Am J Obstet Gyn. 1938; 35: 1004-1009
        • Paterson B.A.
        • Tabrizi S.N.
        • Garland S.M.
        • Fairley C.K.
        • Bowden F.J.
        The tampon test for trichomoniasis: a comparison between conventional methods and a polymerase chain reaction for Trichomonas vaginalis in women.
        Sex Transm Infect. 1998; 74: 136-139
        • Cudmore S.L.
        • Delgaty K.L.
        • Hayward-McClelland S.F.
        • Petrin D.P.
        • Garber G.E.
        Treatment of infections caused by metronidazole-resistant Trichomonas vaginalis.
        Clin Microbiol Rev. 2004; 17: 783-793
        • Kuberski T.
        Trichomonas vaginalis associated with nongonococcal urethritis and prostatitis.
        Sex Transm Dis. 1980; 7: 134-136
        • Gupta P.K.
        • Frost J.K.
        Cytopathology and histopathology of the female genital tract in Trichomonas vaginalis infection.
        in: Honigberg B.M. Trichomonas parasitic in humans. Springer-Verlag, New York1990: 274-290
        • Heine P.
        • MacGregor J.A.
        Trichomonas vaginalis: a re-emerging pathogen.
        Clin Obstet Gynecol. 1993; 36: 137-1114
        • Nye M.B.
        • Schwebke J.R.
        • Body B.A.
        Comparison of APTIMA Trichomonas vaginalis transcription-mediated amplification to wet mount microscopy, culture, and polymerase chain reaction for diagnosis of trichomoniasis in men and women.
        Am J Obstet Gynecol. 2009; 200 (188 e7): 188 e1
        • Huppert J.S.
        • Mortensen J.E.
        • Reed J.L.
        • Kahn J.A.
        • Rich K.D.
        • Miller W.C.
        • et al.
        Rapid antigen testing compares favorably with transcription mediated amplification assay for the detection of Trichomonas vaginalis in young women.
        Clin Infect Dis. 2007; 45: 194-198
        • Lobo T.T.
        • Feiho G.
        • Carvalho S.E.
        • Costa P.L.
        • Chagas C.
        • Xavier J.
        • et al.
        A comparative evaluation of the Papanicolaou test for the diagnosis of trichomoniasis.
        Sex Transm Dis. 2003; 30: 694-699
        • Andrea S.B.
        • Chapin K.C.
        Comparison of Aptima Trichomonas vaginalis transcription-mediated amplification assay and BD affirm VPIII for detection of T. vaginalis in symptomatic women: performance paramenters and epidemiological implications.
        J Clin Microbiol. 2011; 49: 866-869
        • Thin R.N.
        • Symonds M.A.E.
        • Booker R.
        • Cook S.
        • Langlet F.
        Double-blind comparison of a single dose and a five-day course of metronidazole in the treatment of trichomoniasis.
        Br J Ven Dis. 1979; 55: 354-356
        • Schmid G.
        • Narcisi E.
        • Mosure D.
        • Secor W.E.
        • Higgins J.
        • Moreno H.
        Prevalence of metronidazole-resistant Trichomonas vaginalis in a gynecology clinic.
        J Reprod Med. 2001; 46: 545-549
        • Forna F.
        • Gulmezoglu A.M.
        Interventions for treating trichomoniasis in women.
        Cochrane Database Syst Rev. 2003; 2: CD000218
        • Sorvillo F.
        • Kerndt P.
        Trichomonas vaginalis and amplification of HIV-1 transmission.
        Lancet. 1998; 351: 213-214
        • Health Canada
        (Updated on December 20, 2013. Available at)Guidance Document for Industry and Practitioners - Special Access Programme for Drugs. Health Canada, Ottawa2013 (Accessed on May 17, 2014)
      1. (Available at:)Trichomoniasis. Centers for Disease Control, Atlanta (GA)2013 (Accessed on January 10, 2015.)
        • Ling J.
        • Christensen J.
        A double-blind study of the value of treatment with a single dose tinidazole of partners to females with trichomoniasis.
        Acta Obstet Gynecol Scand. 1981; 60: 199-201
        • Klebanoff M.A.
        • Carey J.C.
        • Hauth J.C.
        • Hillier S.L.
        • Nugent R.P.
        • Thom E.A.
        • et al.
        National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic Trichomonas vaginalis infection.
        N Engl J Med. 2001; 345: 487-493
        • Burtin P.
        • Taddio A.
        • Ariburnu O.
        • Einarson T.R.
        • Koren G.
        Safety of metronidazole in pregnancy: a meta-analysis.
        Am J Obstet Gynecol. 1995; 172: 525-529
        • Spiegel C.A.
        • Amsel R.
        • Eschenbach D.
        • Schoenknecht F.
        • Holmes K.K.
        Anaerobic bacteria in nonspecific vaginitis.
        N Engl J Med. 1980; 303: 601-607
        • Eschenbach D.A.
        Bacterial vaginosis: emphasis on upper genital tract complications.
        Obstet Gynecol Clin North Am. 1989; 16: 593-610
        • Hill G.B.
        • Eschenbach D.A.
        • Holmes K.K.
        Bacteriology of the vagina.
        Scand J Urol Nephrol Suppl. 1985; 86: 23-39
        • Hillier S.L.
        Diagnostic microbiology of bacterial vaginosis.
        Am J Obstet Gynecol. 1993; 169: 455-459
        • Rein M.F.
        • Holmes K.K.
        Non-specific vaginitis, vulvovaginal candidiasis, and trichomoniasis: clinical features, diagnosis and management.
        Curr Clin Top Infect Dis. 1983; 4: 281-315
        • Fleury F.J.
        Adult vaginitis.
        Clin Obstet Gynecol. 1987; 24: 407-438
        • Hillier S.L.
        • Nugent R.P.
        • Eschenbach D.A.
        • Krohn M.A.
        • Gibbs R.S.
        • Martin D.H.
        • et al.
        Vaginal Infections and Prematurity Study Group. Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant.
        N Engl J Med. 1995; 333: 1737-1742
        • Gravett M.G.
        • Hammel D.
        • Eschenbach D.A.
        • Holmes K.K.
        Preterm labor associated with subclinical amniotic fluid infection and with bacterial vaginosis.
        Obstet Gynecol. 1986; 67: 229-237
        • Minkoff H.
        • Brunebaum A.N.
        • Schwartz R.H.
        • Feldman J.
        • Cummings M.
        • Crombleholme W.
        • et al.
        Risk factors for prematurity and premature rupture of membranes: a prospective study of the vaginal flora in pregnancy.
        Am J Obstet Gynecol. 1984; 150: 965-972
        • Leitich H.
        • Bodner-Adler B.
        • Brunbauer M.
        • Kaider A.
        • Egarter C.
        • Husslein P.
        Bacterial vaginosis as a risk factor for preterm delivery: a meta-analysis.
        Am J Obstet Gynecol. 2003; 189: 139-147
        • Hillier S.L.
        • Martius J.
        • Krohn M.A.
        • Kiviat N.
        • Holmes K.K.
        • Eschenbach D.A.
        A case-control study of chorioamnionic infection and histologic chorioamnionitis in prematurity.
        N Engl J Med. 1988; 319: 972-978
        • Watts D.H.
        • Krohn M.A.
        • Hillier S.L.
        • Eschenbach D.A.
        Bacterial vaginosis as a risk factor for post-cesarean endometritis.
        Obstet Gynecol. 1990; 75: 52-58
        • Soper D.E.
        • Bump R.C.
        • Hunt W.G.
        Bacterial vaginosis and trichomonas vaginitis are risk factors for cuff cellulites after abdominal hysterectomy.
        Am J Obstet Gynecol. 1990; 163: 1016-1023
        • Korn A.P.
        • Bolan G.
        • Padian N.
        • Ohm-Smith M.
        • Schacter J.
        • Landers D.V.
        Plasma cell endometritis in women with symptomatic bacterial vaginosis.
        Obstet Gynecol. 1995; 85: 387-390
        • Wiesenfeld H.C.
        • Hillier S.L.
        • Krohn M.A.
        • Amortegui A.A.
        • Heine R.P.
        • Landers D.V.
        • et al.
        Lower genital tract infection and endometritis: insight into subclinical pelvic inflammatory disease.
        Obstet Gynecol. 2002; 100: 456-463
        • Goldenberg R.
        • Klebanoff M.
        • Nugent R.
        • Krohn M.
        • Hillier S.
        • Andrews W.
        • Infections Vaginal
        • Prematurity Study Group
        Bacterial colonization of the vagina during pregnancy in four ethnic groups.
        Am J Obstet Gynecol. 1996; 174: 1618-1621
        • Jonsson M.
        • Karlsson R.
        • Rylander E.
        • Gustavsson A.
        • Wadell G.
        The associations between risk behaviour and reported history of sexually transmitted diseases, among young women: a population based study.
        Int J STD AIDS. 1997; 8: 501-505
        • Hawes S.E.
        • Hillier S.L.
        • Benedetti J.
        • Stevens C.E.
        • Koutsky L.A.
        • Wolner-Hanssen P.
        • et al.
        Hydrogen peroxide-producing lactobacilli and acquisition of vaginal infections.
        J Infect Dis. 1996; 174: 1058-1063
        • Brown J.M.
        • Hess K.L.
        • Brown S.
        • Murphy C.
        • Waldman A.L.
        • Hezareh M.
        Intravaginal practices and risk of bacterial vaginosis and candidiasis infection among a cohort of women in the United States.
        Obstet Gynecol. 2013; 121: 773-780
        • Verstraelen H.
        • Verhelst R.
        • Vaneechoutte M.
        • Temmerman M.
        The epidemiology of bacterial vaginosis in relation to sexual behaviour.
        BMC Infect Dis. 2010; 10: 81
        • Fethers K.A.
        • Fairley C.K.
        • Hocking J.S.
        • Gurrin L.C.
        • Bradshaw C.S.
        Sexual risk factors and bacterial vaginosis: a systematic review and meta-analysis.
        Clin Infect Dis. 2008; 47: 1426-1435
        • Amsel R.
        • Totten P.A.
        • Spiegel C.A.
        • Chen K.C.S.
        • Eschenbach D.
        • Holmes K.K.
        Nonspecific vaginitis: diagnostic criteria and microbial and epidemiologic associations.
        Am J Med. 1983; 74: 14-22
        • Nugent R.P.
        • Krohn M.A.
        • Hillier S.L.
        Reliability of diagnosing bacterial vaginosis is improved by a standardized method of Gram stain interpretation.
        J Clin Microbiol. 1991; 29: 297-301
        • Lugo-Miro V.I.
        • Green M.
        • Mazur L.
        Comparison of different metronidazole therapeutic regimens for bacterial vaginosis.
        A meta-analysis. JAMA. 1992; 268: 92-95
        • Hanson J.M.
        • McGregor J.A.
        • Hillier S.L.
        • Eschenbach D.A.
        • Kreutner A.K.
        • Galask A.P.
        • et al.
        Metronidazole for bacterial vaginosis. A comparison of vaginal gel vs. oral therapy.
        J Reprod Med. 2000; 45: 889-896
        • Hillier S.
        • Lipinski C.
        • Briselden A.M.
        • Eschenbach D.A.
        Efficacy of intravaginal 0.75% metronidazole gel for treatment of bacterial vaginosis.
        Obstet Gynecol. 1993; 81: 963-967
        • Livengood C.H.
        • Ferris D.G.
        • Wiesenfeld H.C.
        • Hillier S.L.
        • Soper D.E.
        • Nyirjesy P.
        • et al.
        Effectiveness of two tinidazole regimens in treatment of bacterial vaginosis. A randomized controlled trial.
        Obstet Gynecol. 2007; 110: 302-309
        • Schwebke J.R.
        • Desmond R.A.
        Tinidazole vs metronidazole for the treatment of bacterial vaginosis.
        Am J Obstet Gynecol. 2011; 204: 211.e1-211.e6
        • Hay P.
        Recurrent bacterial vaginosis.
        Curr Infect Dis Rep. 2000; 2: 506-512
        • Koumans E.H.
        • Markowitz L.E.
        Hogan V; CDC BV Working Group. Indications for therapy and treatment recommendations for bacterial vaginosis in nonpregnant and pregnant women: a synthesis of data.
        Clin Infect Dis. 2002; 35: S152-S172
        • Bradshaw C.S.
        • Morton A.N.
        • Hocking J.
        • Garland S.M.
        • Morris M.B.
        • Moss L.M.
        • et al.
        High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence.
        J Infect Dis. 2006; 193: 1478-1486
        • Sobel J.D.
        • Ferris D.
        • Schwebke J.
        • Nyirjesy P.
        • Wiesenfeld H.C.
        • Peipert J.
        • et al.
        Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis.
        Am J Obstet Gynecol. 2006; 194: 1283-1289
        • Ya W.
        • Reifer C.
        • Miller L.E.
        Efficacy of vaginal probiotic capsules for recurrent bacterial vaginosis: a double-blind, randomized, placebo- controlled study.
        Am J Obstet Gynecol. 2010; 203: 120.e1-120.e6
        • Petersen E.E.
        • Magnani P.
        Efficacy and safety of vitamin C vaginal tablets in the treatment of non-specific vaginitis. A randomised, double blind, placebo-controlled trial.
        Eur J Ob Gyn Reprod Biol. 2004; 117: 70-75
        • Yudin M.H.
        Money DM; Society of Obstetricians and Gynaecologists of Canada Infectious Diseases Committee. Screening and management of bacterial vaginosis in pregnancy. SOGC Clinical Practice Guideline, No. 211, August 2008.
        J Obstet Gynaecol Can. 2008; 30: 702-708
        • Woolf S.H.
        • Battista R.N.
        • Angerson G.M.
        • Logan A.G.
        • Eel W.
        Canadian Task Force on Preventive Health Care. New grades for recommendations from the Canadian Task Force on Preventive Health Care.
        CMAJ. 2003; 169: 207-208

      Linked Article